Risk of cervical HPV infection and prevalence of vaccine-type and other high-risk HPV types among sexually active teens and young women (13–26 years) enrolled in the VALHIDATE study

HPV vaccination is expected to reduce the incidence of cervical cancer. The greatest and the earliest health gains will be ensured by high vaccine coverage among all susceptible people. The high costs and the risk of a reduced cost/effectiveness ratio in sexually active girls still represent the mai...

Descripción completa

Detalles Bibliográficos
Autores principales: Orlando, Giovanna, Fasolo, Michela, Mazza, Francesca, Ricci, Elena, Esposito, Susanna, Frati, Elena, Zuccotti, Gian Vincenzo, Cetin, Irene, Gramegna, Maria, Rizzardini, Giuliano, Tanzi, Elisabetta, group, VALHIDATE study
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896517/
https://www.ncbi.nlm.nih.gov/pubmed/24423757
http://dx.doi.org/10.4161/hv.27682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896517/
https://www.ncbi.nlm.nih.gov/pubmed/24423757
http://dx.doi.org/10.4161/hv.27682

Ejemplares similares